Norris Cotton Cancer CenterNorris Cotton Cancer Center
In This Section
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 (Umbralisib) in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy
Principal Investigator (?)
Study Number
This is a Phase 2, open-label, study of TGR-1202, a PI3K delta inhibitor, administered as a single agent in Chronic Lymphocytic Leukemia (CLL) patients who are intolerant to prior BTK inhibitors (ibrutinib, other) or prior PI3K delta inhibitors (idelalisib, other) 
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)


View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.